<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tacrolimus (FK506)/<z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil (MMF) has been demonstrated to be an effective salvage therapy for steroid-resistant <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD), but its effectiveness as prophylaxis for <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (aGVHD) is unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the safety and efficacy of FK506/MMF in preventing aGVHD and sparing the use of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> in childhood and adolescent allogeneic stem cell transplant (AlloSCT) recipients </plain></SENT>
<SENT sid="2" pm="."><plain>Thirty-four childhood and adolescent patients (median age, 7 years; range, 0.5-21 years; 24 males and 10 females) undergoing 37 AlloSCTs for malignant (n = 22) and nonmalignant (n = 12) disorders received FK506 (0.03 mg/kg/d by continuous intravenous infusion) and MMF (15 mg/kg per dose orally or intravenously twice daily) </plain></SENT>
<SENT sid="3" pm="."><plain>Stem cell sources included 22 umbilical cord blood donors (21 unrelated and 1 related), 6 related bone marrow donors, and 9 related peripheral blood donors </plain></SENT>
<SENT sid="4" pm="."><plain>Malignant diagnoses included 7 <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo>, 3 <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo>, 1 <z:hpo ids='HP_0004836'>acute promyelocytic leukemia</z:hpo>, 2 non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 4 Hodgkin diseases, 3 <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and 2 <z:hpo ids='HP_0003006'>neuroblastomas</z:hpo>; nonmalignant diagnoses included 2 beta-<z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemias</z:e>, 1 sickle cell disease, 4 <z:hpo ids='HP_0001915'>aplastic anemias</z:hpo>, 1 Wiskott-<z:e sem="disease" ids="C0043194" disease_type="Disease or Syndrome" abbrv="">Aldrich syndrome</z:e>, 1 Hurler syndrome, 2 hemophagocytic lymphohistiocytoses, and 1 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The probability of developing grade &gt; or =II aGVHD was 45.4% +/- 9.7% (7 related bone marrow/related peripheral blood; 5 umbilical cord blood), and for <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD it was 38.1% +/- 19.7% </plain></SENT>
<SENT sid="6" pm="."><plain>FK506/MMF was well tolerated </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients had grade III to IV neurotoxicity (<z:hpo ids='HP_0001289'>disorientation</z:hpo> and <z:hpo ids='HP_0002352'>leukoencephalopathy</z:hpo>); 4 patients developed grade III to IV nephrotoxicity (<z:hpo ids='HP_0000001'>all</z:hpo> received concomitant nephrotoxins) </plain></SENT>
<SENT sid="8" pm="."><plain>Patients who achieved target <z:chebi fb="0" ids="168396">mycophenolic acid</z:chebi> levels (1.0-3.5 microg/mL) before day +30 had a significantly reduced incidence of developing grade &gt;/=II aGVHD (16.7% +/- 15.2% versus 100%; P &lt;.02) </plain></SENT>
<SENT sid="9" pm="."><plain>These results suggest that FK506/MMF is well tolerated and may be a safe and effective <z:chebi fb="0" ids="44185">methotrexate</z:chebi>- and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi>-sparing alternative GVHD prophylaxis regimen after AlloSCT </plain></SENT>
<SENT sid="10" pm="."><plain>Further pharmacokinetic and pharmacodynamic studies are ongoing in pediatric and adolescent AlloSCT recipients to define optimal MMF dosing </plain></SENT>
</text></document>